# FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

> **NCT06303505** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tubulis GmbH** · enrollment: 250 (estimated)

## Conditions studied

- Ovarian Cancer
- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** TUB-040

## Key facts

- **NCT ID:** NCT06303505
- **Lead sponsor:** Tubulis GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-12
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06303505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06303505, "FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC". Retrieved via AI Analytics 2026-08-09 from https://api.ai-analytics.org/clinical/NCT06303505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*